SUVEN Life Sciences Ltd

News Release

Hyderabad, India (June 11, 2007)

SUVEN'S UNIT-III RECEIVES US FDA ACCEPTANCE

Suven Life Sciences Limited an ISO 9001, ISO 14001 and OHSAS 18001 company has undergone US FDA inspection at their facility in Pashamylaram, near Hyderabad for the manufacture and supply of active pharmaceutical ingredients (bulk drugs) under cGMP.

Based on the inspection and the review thereafter US-FDA has classified Suven facility at Pashamylaram as acceptable for manufacture and supply of active pharmaceutical ingredients.

So far Suven Life Sciences has filed 8 DMF's from this facility which is now FDA complaint under cGMP. With partner ANDA approvals Suven can supply the active pharmaceutical ingredients in future thus generating new revenues in due course of time.

Suven Life Sciences is a Hyderabad based Life Science company, a **Collaborative Research Partner** (CRP) in Drug Discovery for a global Pharma major since 2006 is a pioneer in **Contract Research and Manufacturing Services** (CRAMS) since 1995 and **Drug Discovery and Development Support Services** (DDDSS) since 2005. Suven is engaged in discovering new chemical entities in Central Nervous System (CNS) therapeutic areas Viz: Alzheimer's, Cognitive impairment, Dementia, Depression, Parkinson's disease and obesity which are at various phases of preclinical development.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven's commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 190 professionals with the state of the art infrastructure for Drug Discovery and development activities with 40 clinical research professionals and the front end project management services from New Jersey, USA.

For more information on Suven, please visit our Web site at www.suven.com

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;